CoreCap Advisors’s Standard BioTools LAB Stock Holding History

CoreCap Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-151	Closed	-$264	–	3238
2024 Q4	$264	Buy	+151	New	+$281	﹤0.01%	2667

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CoreCap Advisors's LAB Position: Q1 2025 in Review

CoreCap Advisors sold out of Standard BioTools (LAB) in Q1 2025, closing a stake of 151 shares — an estimated $264 sold.

CoreCap Advisors first reported a position in LAB in Q4 2024 and held it in 1 quarter. The position peaked at $264 in Q4 2024. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2025.

CoreCap Advisors reported no remaining Standard BioTools position as of Q1 2025 after selling out during the quarter.
CoreCap Advisors sold 151 Standard BioTools shares in Q1 2025, an estimated $264.
CoreCap Advisors first reported a position in Standard BioTools in Q4 2024 and held it in 1 quarter.
CoreCap Advisors's Standard BioTools position peaked at $264 in Q4 2024.
145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2025.

Based on CoreCap Advisors's 13F filing for Q1 2025, filed 9 May 2025.